Hyperpolarized 129Xe ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	2

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04778046 (ClinicalTrials.gov)	February 15, 2023	26/2/2021	Pulmonary Hypertension SOLAR	Defining a Noninvasive Signature for Pulmonary Vascular Remodeling in Group 3 PH	Interstitial Lung Disease;COPD;Pulmonary Arterial Hypertension	Drug: Hyperpolarized 129Xe	Bastiaan Driehuys	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United States
2	NCT05339386 (ClinicalTrials.gov)	August 29, 2022	13/4/2022	Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension	Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Hyperpolarized Xe129	University of Kansas Medical Center	American Heart Association	Recruiting	18 Years	N/A	All	22		United States